Higuchi Takashi, Oshiro Hiromichi, Zhang Zhiying, Miyake Kentaro, Sugisawa Norihiko, Katsuya Yuki, Yamamoto Norio, Hayashi Katsuhiro, Kimura Hiroaki, Miwa Shinji, Igarashi Kentaro, Zhao Ming, Bouvet Michael, Singh Shree Ram, Tsuchiya Hiroyuki, Hoffman Robert M
AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan.
AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.
Transl Oncol. 2019 Apr;12(4):640-645. doi: 10.1016/j.tranon.2019.01.007. Epub 2019 Feb 23.
The goal of the present study was to determine the efficacy of osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of aggressive EGFR-mutant non-small cell lung cancer (NSCLC), compared to cisplatinum (CDDP) + pemetrexed (PEM). The NSCLC cell line PC-9 expressing green fluorescence protein (PC-9-GFP) was implanted in the brain of nude mice and was treated with CDDP + PEM or AZD9291. Tumors were observed by non-invasive fluorescence imaging. AZD9291 treatment caused tumor regression in contrast to CDDP + PEM which had only a slight inhibitory effect. These results suggest that AZD9291 is a promising clinical option for NSCLC patients with brain metastasis.
本研究的目的是确定第三代表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂奥希替尼（AZD9291）与顺铂（CDDP）+培美曲塞（PEM）相比，在治疗侵袭性EGFR突变非小细胞肺癌（NSCLC）中的疗效。将表达绿色荧光蛋白的NSCLC细胞系PC-9（PC-9-GFP）植入裸鼠脑内，并用CDDP + PEM或AZD9291进行治疗。通过非侵入性荧光成像观察肿瘤。与仅具有轻微抑制作用的CDDP + PEM相比，AZD9291治疗导致肿瘤消退。这些结果表明，AZD9291对于有脑转移的NSCLC患者是一种有前景的临床选择。
